| 1 |
34984651 | Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis. | 2022 Jan |
5 |
| 2 |
35163193 | N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease. | 2022 Jan 23 |
3 |
| 3 |
34014547 | Bridging the Metabolic Parallels Between Neurological Diseases and Cancer. | 2021 |
2 |
| 4 |
34684866 | Two Sides of Quantum-Based Modeling of Enzyme-Catalyzed Reactions: Mechanistic and Electronic Structure Aspects of the Hydrolysis by Glutamate Carboxypeptidase. | 2021 Oct 17 |
1 |
| 5 |
31730793 | N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications. | 2020 Jan |
1 |
| 6 |
33256444 | Association of Missense Mutation in FOLH1 With Decreased NAAG Levels and Impaired Working Memory Circuitry and Cognition. | 2020 Dec 1 |
12 |
| 7 |
30970252 | Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. | 2019 Apr 9 |
5 |
| 8 |
31528698 | Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy. | 2019 |
3 |
| 9 |
28251297 | Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG). | 2017 Jun |
8 |
| 10 |
28326936 | A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA. | 2017 Jan |
2 |
| 11 |
27288079 | Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors. | 2016 |
6 |
| 12 |
27387982 | Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. | 2016 Oct |
3 |
| 13 |
27589333 | Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer. | 2016 Nov |
1 |
| 14 |
26151906 | Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration. | 2015 |
5 |
| 15 |
26269888 | Application of Novel Therapeutic Agents for CNS Injury: NAAG Peptidase Inhibitors | 2015 |
2 |
| 16 |
26459214 | Carborane-containing urea-based inhibitors of glutamate carboxypeptidase II: Synthesis and structural characterization. | 2015 Nov 15 |
2 |
| 17 |
24647901 | Detection and quantitation of glutamate carboxypeptidase II in human blood. | 2014 May |
4 |
| 18 |
23525278 | Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme. | 2013 Jul |
4 |
| 19 |
23891752 | S1 pocket of glutamate carboxypeptidase II: a new binding site for amyloid-β degradation. | 2013 Sep 6 |
3 |
| 20 |
22124883 | Glutamate carboxypeptidase II gene polymorphisms and neural tube defects in a high-risk Chinese population. | 2012 Mar |
2 |
| 21 |
22214450 | Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. | 2012 |
4 |
| 22 |
22304711 | The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. | 2012 |
2 |
| 23 |
22304714 | NAAG, NMDA receptor and psychosis. | 2012 |
1 |
| 24 |
22304717 | Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. | 2012 |
4 |
| 25 |
22570482 | Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia. | 2012 Jun 22 |
1 |
| 26 |
22750589 | NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. | 2012 Aug 21 |
2 |
| 27 |
23169655 | Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. | 2012 Dec 4 |
2 |
| 28 |
20434427 | Bioanalysis of N-acetyl-aspartyl-glutamate as a marker of glutamate carboxypeptidase II inhibition. | 2010 Sep 1 |
3 |
| 29 |
21074428 | The discovery and structure-activity relationships of indole-based inhibitors of glutamate carboxypeptidase II. | 2010 Dec 15 |
2 |
| 30 |
19403271 | Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. | 2009 Jun |
2 |
| 31 |
19487395 | Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? | 2009 Jul |
3 |
| 32 |
18234225 | Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. | 2008 Mar 7 |
2 |
| 33 |
17150306 | Expression of glutamate carboxypeptidase II in human brain. | 2007 Feb 23 |
1 |
| 34 |
17241157 | Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus. | 2007 Jan |
5 |
| 35 |
18066809 | 2-5A ligands--a new concept for the treatment of prostate cancer. | 2007 |
2 |
| 36 |
16467855 | Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. | 2006 Mar 22 |
2 |
| 37 |
15836619 | Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors. | 2005 May |
8 |
| 38 |
12917384 | GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. | 2004 Jan |
4 |
| 39 |
14560319 | Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. | 2004 Jan |
1 |
| 40 |
15027864 | Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. | 2004 Mar 25 |
2 |
| 41 |
15136672 | Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. | 2004 May 11 |
1 |
| 42 |
15140187 | NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. | 2004 May |
1 |
| 43 |
15152093 | Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. | 2004 Jun |
4 |
| 44 |
20641246 | Quantum dot-prostate-specific membrane antigen antibody J591 | 2004 |
1 |
| 45 |
20641248 | N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-S-[11C]methyl-L-cysteine | 2004 |
2 |
| 46 |
20641404 | 64Cu-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-anti-prostate-specific membrane antigen 3/A12 monoclonal antibody | 2004 |
1 |
| 47 |
20641595 | N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine | 2004 |
2 |
| 48 |
20662139 | IRDye800-2-(3-{5-[7-(5-amino-1-carboxy-pentylcarbamoyl)-heptanoylamino]-1-carboxy-pentyl}-ureido)-pentanedioic acid | 2004 |
1 |
| 49 |
21634075 | Quantum dot 800–prostate-specific membrane antigen antibody J591 | 2004 |
1 |
| 50 |
22379638 | 89Zr-Desferrioxamine B-7E11 anti-prostate-specific membrane antigen monoclonal antibody | 2004 |
1 |